Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation

Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies

Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526

Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex

Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793

Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants

Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750

Synaptic Dysfunction in Depression: Potential Therapeutic Targets

Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms

Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260

Mechanisms of ketamine action as an antidepressant

Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127

Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors

Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103

Bipolar disorders

McIntyre, R. S., Berk, M., Brietzke, E., Goldstein, B. I., López-Jaramillo, C., Kessing, L. V., Malhi, G. S., Nierenberg, A. A., Rosenblat, J. D., Majeed, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31544-0 · Cited by 1,047

A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression

Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963

Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression

Rodrigues, N. B., Chen-Li, D. C. J., Vincenzo, J. D. D., Juneja, A., Pinder, B. D., McIntyre, R. S., & Rosenblat, J. D. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241238284 · Cited by 13

Update on the assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form-2 (ATHF-SF2)

Sackeïm, H. A., Aaronson, S. T., Bunker, M. T., Conway, C. R., George, M. S., McAllister-Williams, H., Prudic, J., Thase, M. E., Young, A. H., & Rush, A. J. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.05.046 · Cited by 15

A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists

Kwan, A. T. H., Rosenblat, J. D., Mansur, R. B., Rhee, T. G., Teopiz, K. M., Le, G. H., Wong, S., Cao, B., Ho, R., & McIntyre, R. S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.07.128 · Cited by 13

Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression

Price, M. Z., & Price, R. L. (2024) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2024.100104 · Cited by 15

Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression

Weissman, C. R., Bermudes, R. A., Voigt, J. D., Liston, C. M., Williams, N., Blumberger, D. M., Fitzgerald, P. B., & Daskalakis, Z. J. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.22com14575 · Cited by 15

Antidepressant use in bipolar disorder: Shifting focus from ‘Whether’ to ‘Whom’

Fico, G., & Vieta, E. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.04.004 · Cited by 13

Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence

Di Vincenzo, J. D., Lipsitz, O., Rodrigues, N. B., Lee, Y., Gill, H., Kratiuk, K., Subramaniapillai, M., Mansur, R., McIntyre, R. S., & Rosenblat, J. D. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.09.002 · Cited by 12

S-ketamine exposure in early postnatal period induces social deficit mediated by excessive microglial synaptic pruning

Zhong, H., Xue, R., Han, Y., Liu, L., Zhao, J., Cai, M., Wang, S., Wei, P., Zhao, G., & Dong, H. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02949-7 · Cited by 12

Comparative safety and tolerability of ketamine and esketamine for major depressive disorder: a systematic review and meta-analysis

Guo, H., Tang, L., He, M., Tang, W., Liu, J., Wu, S., Yuan, S., Wang, J., & Tang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1681060 · Cited by 15

Therapeutic Protocols Using Ketamine and Esketamine for Depressive Disorders: A Systematic Review

FREIND, J. M. K., Beserra, F. R., Menezes, B. S., & Mograbi, D. C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2248989 · Cited by 12

Listening to music during intranasal (es)ketamine therapy in patients with treatment-resistant depression correlates with better tolerability and reduced anxiety

Hauser, J., Sarlon, J., Liwinski, T., Brühl, A. B., & Lang, U. E. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1327598 · Cited by 16

Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depression

Yan, R., Marshall, T., Khullar, A., Nagle, T., Knowles, J., Malkin, M., Chubbs, B., & Swainson, J. (2024) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253241231264 · Cited by 12

Predicting non-response to ketamine for depression: An exploratory symptom-level analysis of real-world data among military veterans

Miller, E. A., Afshar, H. T., Mishra, J., McIntyre, R. S., & Ramanathan, D. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115858 · Cited by 12

Single arketamine in treatment resistant depression: Presentation of 3 cases with regard to sick-leave duration

Włodarczyk, A., Słupski, J., Szarmach, J., & Cubała, W. J. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104016 · Cited by 12

The role of KCNQ channel activators in management of major depressive disorder

Meshkat, S., Kwan, A. T. H., Le, G. H., Wong, S., Rhee, T. G., Ho, R., Teopiz, K. M., Cao, B., & McIntyre, R. S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.05.067 · Cited by 12

Rapid and long-lasting effects of subcutaneous esketamine on suicidality: An open-label study in patients with treatment-resistant depression

Lopes, E. I. T. C., Cavalcanti-Ribeiro, P., Palhano-Fontes, F., Gonçalves, K. T. D. C., Nunes, E. A., Lima, N. B. D. M., dos Santos, N. C., de Brito, A. J. C., de Araújo, D. B., & Coelho, N. L. G. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.06.020 · Cited by 12

Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD)

Olivier, B., & Olivier, J. D. A. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-4402-2_3 · Cited by 12

Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies

Morrison, R. L., Singh, J. B., Daly, E., Fedgchin, M. M., Ochs-Ross, R., Karcher, K., Lane, R., Cooper, K. L., Sanacora, G., Maruff, P. T., et al. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae046 · Cited by 12

Is there a risk of esketamine misuse in clinical practice?

Roncero, C., Torres, M. M., Szerman, N., Torrens, M., Vega, P., Andrés-Olivera, P., & Alvarez, E. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241310685 · Cited by 16

Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence

Vincenzo, J. D. D., Lipsitz, O., Rodrigues, N. B., Jones, B. D. M., Gill, H., Lee, Y. L., Lui, L. M. W., Teopiz, K. M., Ho, R., Lin, K., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114321 · Cited by 12

Efficacy of ketamine for comorbid depression and acute or chronic pain: A systematic review

Balachandran, A., Tassone, V. K., Adamsahib, F., Passa, A.-M. D., Kuburi, S., Demchenko, I., Ladha, K. S., & Bhat, V. (2022) · Frontiers in Pain Research · doi:10.3389/fpain.2022.1022767 · Cited by 13

Ketamine treatment for depression: A model of care

Bayes, A. J., Dong, V., Martin, D. M., Alonzo, A., Kabourakis, M., & Loo, C. K. A. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211039166 · Cited by 12

Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression: a single-case report

Moccia, L., Lanzotti, P., Pepe, M., Palumbo, L., Janiri, D., Camardese, G., Bentivoglio, A. R., Nicola, M. D., Calabresi, P., & Sani, G. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000378 · Cited by 12

Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics

Kojic, M., Saelens, J., Kadriu, B., Zarate, C. A., & Kraus, C. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_313 · Cited by 12

Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report

Garel, N., Greenway, K. T., Dinh-Williams, L.-A. L., Thibault-Levesque, J., Jutras-Aswad, D., Turecki, G., Rej, S., & Richard-Devantoy, S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01689-y · Cited by 13

Ketamine supresses REM sleep and markedly increases EEG gamma oscillations in the Wistar Kyoto rat model of treatment-resistant depression

Kántor, S., Lanigan, M., Giggins, L., Lione, L. A., Magomedova, L., de Lannoy, I., Upton, N., & Duxon, M. S. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114473 · Cited by 13

Ketamine Use in Child and Adolescent Psychiatry: Emerging Data in Treatment-Resistant Depression, Insights from Adults, and Future Directions

Ryan, K., & Hosanagar, A. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01432-w · Cited by 11

Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers

Mathai, D. S., Hilbert, S. N., Sepeda, N. D., Strickland, J. C., Griffiths, R. R., & Garcia‐Romeu, A. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0035 · Cited by 11

Exploring the role of esketamine in alleviating depressive symptoms in mice via the PGC-1α/irisin/ERK1/2 signaling pathway

Hu, N., Chen, X., Chen, C., Liu, X., Yi, P., Xu, T., Jia, J., Feng, J., Zhang, C., & Wang, X. (2023) · Scientific Reports · doi:10.1038/s41598-023-43684-9 · Cited by 11

Efficacy and safety of ketamine-assisted electroconvulsive therapy in major depressive episode: a systematic review and network meta-analysis

Rhee, T. G., Shim, S. R., Popp, J. H., Trikalinos, T. A., Rosenheck, R. A., Kellner, C. H., Seiner, S. J., Espinoza, R. T., Forester, B. P., & McIntyre, R. S. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02366-8 · Cited by 12

Music as an Intervention to Improve the Hemodynamic Response of Ketamine in Depression

Greenway, K. T., Garel, N., Dinh-Williams, L.-A., Beaulieu, S., Turecki, G., Rej, S., & Richard‐Devantoy, S. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.54719 · Cited by 11

Major challenges in youth psychopathology: treatment-resistant depression. A narrative review

Menculini, G., Cinesi, G., Scopetta, F., Cardelli, M., Caramanico, G., Balducci, P. M., Giorgi, F. D., Moretti, P., & Tortorella, A. A. V. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1417977 · Cited by 13

Psilocybin in pharmacotherapy of obsessive-compulsive disorder

Owe-Larsson, M., Kamińska, K., Buchalska, B., Mirowska-Guzel, D. M., & Cudnoch‐Jędrzejewska, A. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00633-1 · Cited by 13

Prefrontal cortex astrocytes in major depressive disorder: exploring pathogenic mechanisms and potential therapeutic targets

Pan, Y., Xiang, L., Zhu, T., Wang, H., Xu, Q., Liao, F., He, J., & Wang, Y. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02487-9 · Cited by 11

The mediational role of cognitive function on occupational outcomes in persons with major depressive and bipolar disorder

Tamura, J. K., Harangi, D., Rodrigues, N. B., Mansur, R. B., Subramaniapillai, M., Johnson, D. E., Rosenblat, J. D., Lee, Y. L., Vincenzo, J. D. D., Ho, R., et al. (2024) · CNS Spectrums · doi:10.1017/s1092852924002293 · Cited by 13

Assessment of complement cascade components in patients with major depressive disorder

Quintanilla, B., Greenstein, D. K., Tripathi, A., Bartosh, A., Yuan, P., Zarate, C. A., & Pillai, A. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.03.009 · Cited by 11

The microglial state transition as a novel mechanism by which fresh Baihe Dihuang decoction prevents depression by regulating SIRT1/HMGB1 signaling

Cao, L.-H., Wang, Z.-Z., Zhao, H., Tian, S., He, H., Miao, J., Huang, S., Wang, X., Song, Y.-G., Kang, L., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156718 · Cited by 12

Antidepressant effects of ershiwei roudoukou pills and its active ingredient Macelignan: Multiple mechanisms involving oxidative stress, neuroinflammation and synaptic plasticity

Wang, Y., Chen, L., Zhong, X.-L., Liu, Q., Li, W., Cheng, Y., & Du, Y. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03378-4 · Cited by 13

The drug liking and craving questionnaire (DLCQ) to evaluate addiction risk for ketamine and esketamine

Wang, J. C.-C., Khullar, A., McIntyre, R. S., & Swainson, J. (2021) · Psychiatry Research Communications · doi:10.1016/j.psycom.2021.100018 · Cited by 11

Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression

Lapidos, A., Lopez-Vives, D., Sera, C. E., Ahearn, E., Vest, E., Senic, I., Voort, J. L. V., Frye, M. A., Goes, F. S., Achtyes, E. D., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.11.090 · Cited by 11

The effects of (2R,6R)-hydroxynorketamine on oxycodone withdrawal and reinstatement

Drinkuth, C. R., Lehane, M. J., & Sartor, G. C. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.110987 · Cited by 10

New Insights Into Major Depression and the Treatment of Bipolar Depression

Kalin, N. H. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21101042 · Cited by 11

Back to the Future: Esmethadone, the (Maybe) Nonopiate Opiate, and Depression

Nemeroff, C. B. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21121204 · Cited by 11

Personalizing esketamine treatment in TRD and TRBD: the role of mentalization, cognitive rigidity, psychache, and suicidality

Olivola, M., Mazzoni, F., Tarantino, B., Guffanti, A., Marcatili, M., Macellaro, M., Girone, N., Martiadis, V., Raffone, F., Prodi, T., et al. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1736114 · Cited by 10

Approach to Diagnosis and Management of Treatment-Resistant Depression

Rikhani, K., Vas, C., & Jha, M. K. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.011 · Cited by 11

Multidisciplinary development of guidelines for ketamine treatment for treatment-resistant major depression disorder for use by adult specialist mental health services in New Zealand

Beaglehole, B., Glue, P., Clarke, M., & Porter, R. (2023) · BJPsych Open · doi:10.1192/bjo.2023.577 · Cited by 10

Ketamine promptly normalizes excess norepinephrine and enhances dopamine neuronal activity in Wistar Kyoto rats

Daniels, S., Mansari, M. E., Hamoudeh, R. A., & Blier, P. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1276309 · Cited by 11

Efficacy of esketamine for perinatal depression: a systematic review and meta-analysis

Wong, S., Le, G. H., Kwan, A. T. H., Teopiz, K. M., Rhee, T. G., Ho, R., Rosenblat, J. D., Mansur, R. B., & McIntyre, R. S. (2024) · CNS Spectrums · doi:10.1017/s1092852924000452 · Cited by 10

The ketamine chameleon: history, pharmacology, and the contested value of experience

Diep, D., de la Salle, S., Lévesque, J. T., Lifshitz, M., Garel, N., & Greenway, K. T. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2459377 · Cited by 10

Esketamine alleviated cardiomyocyte ferroptosis induced by oxygen–glucose deprivation/reoxygenation (OGD/R) via cyclic GMP-AMP synthase interactor

Ouyang, J., Xiao, W., Wu, D., Bai, M., Zhao, Q., & Li, Y. (2025) · Cytotechnology · doi:10.1007/s10616-025-00723-9 · Cited by 10

Safety considerations and risk mitigation strategies for ketamine use: a comprehensive review

Sayad, R., Elsaeidy, A. S., Anis, A. M., Atef, M. M., Hawash, E. A., Saad, H. A., Hamad, K., & Kohaf, N. A. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003232 · Cited by 10

Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the use of ketamine in psychiatric practice

Hussain, S., Gale, C. K., Sarma, S., Smith, J. P., Bayes, A. J., & Loo, C. K. A. (2025) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674251333577 · Cited by 10

The effect of esketamine on postoperative anxiety and depression in patients with thyroid cancer: A randomized, double-blind, placebo-controlled, parallel-group trial

Bi, X., Dai, J., & Li, J. (2025) · Medicine · doi:10.1097/md.0000000000042284 · Cited by 10

Ketamine and Esketamine for Late-Life Depression: A Systematic Review of Efficacy, Safety, and Tolerability

Sukhdeo, R., Tamura, J. K., Dri, C. E., & McIntyre, R. S. (2025) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2025.08.001 · Cited by 12

Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment

McIntyre, R. S., Rodrigues, N. B., Lipsitz, O., Lee, Y. L., Cha, D. S., Gill, H., Lui, L. M. W., Subramaniapillai, M., Kratiuk, K., Ho, R., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.03.053 · Cited by 12

Changes in neurotrophic signaling pathways in brain areas of the chronic mild stress rat model of depression as a signature of ketamine fast antidepressant response/non-response

Derosa, S., Misztak, P., Mingardi, J., Mazzini, G., Müller, H. K., & Musazzi, L. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110871 · Cited by 10

Alternative metrics for characterizing longer-term clinical outcomes in difficult-to-treat depression: II. Sensitivity to treatment effects

Aaronson, S., Sackeim, H., Jiang, M., Badejo, S., Greco, T., Bunker, M., Conway, C., Demyttenaere, K., Young, A. H., McAllister-Williams, R., et al. (2023) · Australian and New Zealand journal of psychiatry (Print) · doi:10.1177/00048674231209837 · Cited by 11

What clinicians need to know about intranasal esketamine for treatment-resistant depression?

Hope, J., Copolov, D., Tiller, J. W. G., Galbally, M., Hopwood, M., Newton, R., & Keks, N. A. (2023) · Australasian Psychiatry · doi:10.1177/10398562231211171 · Cited by 10

Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic

Rosenblat, J. D., Lipsitz, O., Vincenzo, J. D. D., Rodrigues, N. B., Kratiuk, K., Subramaniapillai, M., Lee, Y. L., Arekapudi, A. K., Abrishami, A., Chau, E. H., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114086 · Cited by 11

Treatment-Resistant Depression

Hughes, M. E., & Levine, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00065-8 · Cited by 10

Ketamine Self-Medication in a Patient with Autism Spectrum Disorder and Comorbid Therapy-Resistant Depression

Özgen, M. H., & van den Brink, W. (2022) · Psychiatry and Clinical Psychopharmacology · doi:10.5152/pcp.2022.22037 · Cited by 9

Effect of intraoperative and/or postoperative esketamine administration on preventing postpartum depression: A systematic review and meta-analysis

Wang, J., Liu, H., & Wei, X. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115890 · Cited by 9

The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS)

Kwan, A. T. H., Rosenblat, J. D., Mansur, R. B., Teopiz, K. M., & McIntyre, R. S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.05.116 · Cited by 9

The association between ketamine and esketamine and suicidality: reports to the Food And Drug Administration Adverse Event Reporting System (FAERS)

McIntyre, R. S., Mansur, R. B., Rosenblat, J. D., Teopiz, K. M., & Kwan, A. T. H. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2368827 · Cited by 9

The effect and mechanism of low-dose esketamine in neuropathic pain-related depression-like behavior in rats

Wang, L., Zhao, S., Shao, J., & Su, C. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149117 · Cited by 11

Psychoactive substances for the treatment of neuropsychiatric disorders

Zhen, Z., Sun, X., Yuan, S., & Zhang, J. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104193 · Cited by 11

Esketamine Nasal Spray in Major Depressive Disorder: A Meta‐Analysis of Randomized Controlled Trials

Wang, Z., Jiang, L., Ma, W., Li, X., Gao, Q., Lian, S., & Yu, W. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3555 · Cited by 12

Effect of Esketamine on Cognitive Recovery After Propofol Sedation for Outpatient Colonoscopy: A Randomized Clinical Trial

Liu, D., Gao, X., Zhuo, Y., Cheng, W., Yang, Y., Wu, X., Yang, H., & Yao, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s503129 · Cited by 9

Novel mechanisms underlying rapid-acting antidepressants: ketamine-like compounds, neurosteroid GABAkines, and psychedelics

Castanheira, S., Gomes, C. V., Bicker, J., & Fortuna, A. C. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104371 · Cited by 10

Ketamine in Clinical Practice: Transitioning from Anesthetic Agent to Psychiatric Therapeutic

Quintero, J.-M., Bustos, R., Lechtig, S., Beltran, S., & Zarate, C. A. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009585330.007 · Cited by 12

Real world effectiveness of maintenance ketamine infusions for treatment-resistant depression in major depressive disorder and bipolar disorder

Haikazian, S., McIntyre, R. S., Meshkat, S., Kratiuk, K., Llach, C.-D., Orsini, D. K., Luch, S. D. D., & Rosenblat, J. D. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116691 · Cited by 9

Mentalization and Emotional-Cognitive Rigidity as predictors of esketamine's effects on Treatment-Resistant Depression: Findings from a prospective observational study

Olivola, M., Mazzoni, F., Tarantino, B., Guffanti, A., Marcatili, M., Motta, F. L., Cornaggia, R. D., Martiadis, V., Prodi, T., Politi, P., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120231 · Cited by 9

Synaptic priming: A framework for pharmacotherapy in depression

Brown, K. A., Ajibola, M. I., Medeiros, G. C., & Gould, T. D. (2025) · Neuron · doi:10.1016/j.neuron.2025.09.010 · Cited by 11

Phosphorylated Ser187-SNAP25-modulated hyperfunction of glutamatergic system in the vmPFC mediates depressive-like behaviors in male mice.

Wang, X.-J., Hou, X., Huo, Y., Wang, D., Fan, X., Lin, X., Yu, W.-D., Cui, C., Guo, J.-Z., & Li, Y.-J. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109691 · Cited by 9

What Should Clinicians Know About Palliative Psychopharmacology?

(2023) · AMA Journal of Ethics · doi:10.1001/amajethics.2023.710 · Cited by 7

Treating Treatment-resistant Depression with Esketamine Nasal Spray When All Therapeutic Options Have Been Exhausted: Clinical Experience from a Spanish Cohort of Expanded Use

Vendrell-Serres, J., Soto-Angona, Ó., Rodríguez‐Urrutia, A., Inzoli, B., González, A., & Ramos‐Quiroga, J. A. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1097 · Cited by 11

Suicide Assessment and Prevention in Bipolar Disorder: How Current Evidence Can Inform Clinical Practice

Izadi, N., Mitchell, R. H. B., Giacobbe, P., Nestor, S. M., Steinberg, R. J., Amini, J., Sinyor, M., & Schaffer, A. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20230011 · Cited by 11

Efficacy of perioperatively application of ketamine on postoperative depressive symptoms in adult patients: A systematic review and meta-analysis with trial sequential analysis

Wei, Q., Li, M., Jiang, Y., & Liu, X. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.02.085 · Cited by 8

Pediatric suicide: Review of a preventable tragedy

Greydanus, D. E., Nazeer, A., Qayyum, Z., Patel, D. R., Rausch, R., Hoang, L.-N., Miller, C., Chahin, S. S., Apple, R. W., Saha, G. K., et al. (2024) · Disease-a-Month · doi:10.1016/j.disamonth.2024.101725 · Cited by 10

Developing an individualized treatment rule for Veterans with major depressive disorder using electronic health records

Zainal, N. H., Bossarte, R. M., Gildea, S. M., Hwang, I. H., Kennedy, C. J., Liu, H., Leung, L. B., Luedtke, A. R., Marx, B. P., Petukhova, M. V., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02500-0 · Cited by 9

Non-improvement predicts subsequent non-response to repeated-dose intravenous ketamine for depression: a re-analysis of a 2-week open-label study in patients with unipolar and bipolar depression

Wang, C., Lan, X., Liu, W., Zhan, Y., Zheng, W., Chen, X., Liu, G., Mai, S., Lu, H., McIntyre, R. S., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03027-2 · Cited by 8

Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI? - Insights from the REAL-ESK study

d’Andrea, G., Miuli, A., Pettorruso, M., Cavallotto, C., Marrangone, C., Cocco, A., Filippis, S. D., Martiadis, V., Andriola, I., Barlati, S., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.004 · Cited by 9

Characterizing the therapeutical use of ketamine for adolescent rats of both sexes: Antidepressant-like efficacy and safety profile

Jornet-Plaza, J., Ledesma‐Corvi, S., & García-Fuster, M. J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117781 · Cited by 8

Towards an expanded neurocognitive account of ketamine’s rapid antidepressant effects

Dai, Y., Harrison, B. J., Davey, C. G., & Steward, T. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf010 · Cited by 11

Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov

Świeczkowski, D., Kwaśny, A., Sadko, K. G., Pruc, M., Gaca, Z., Szarpak, Ł., & Cubała, W. J. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116559 · Cited by 8

Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee

Gutiérrez, G., Vázquez, G. H., Ravindran, N., Lam, R. W. M., Giacobbe, P., Ganapathy, K., Kowara, A., Do, A., Baskaran, A., Nestor, S. M., et al. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986251347360 · Cited by 8

Future Pharmacotherapy for Bipolar Disorders: Emerging Trends and Personalized Approaches

Marano, G., Lisci, F. M., Boggio, G., Marzo, E. M., Abate, F., Sfratta, G., Traversi, G., Mazza, O., Pola, R., Sani, G., et al. (2025) · Future Pharmacology · doi:10.3390/futurepharmacol5030042 · Cited by 8

The Impact of Esketamine on Depression: Targeting Oxidative Stress and Neuronal Apoptosis Through BDNF/TrkB/PI3K/AKT Pathway Activation

Zhang, Y., Cai, Q., Wang, L., & Zhang, B. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s502090 · Cited by 9

Clinical Benefits and Challenges of Esketamine in Elderly Patients During the Perioperative Period

Zhang, S., Bai, C., Xu, M., Li, Y., Han, Y., Jin, Y., & Zhao, X. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s536813 · Cited by 9

Combinations of dextromethorphan for the treatment of mood disorders - a review of the evidence

Parincu, Z., & Iosifescu, D. V. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2192402 · Cited by 9

Molecular Regulation and Therapeutic Applications of Brain-Derived Neurotrophic Factor–Tropomyosin-Related Kinase B Signaling in Major Depressive Disorder Though Its Interaction with Vascular Endothelial Growth Factor and N-Methyl-D-Aspartic Acid Receptors: A Narrative Review

Matsuzaka, Y., & Yashiro, R. (2025) · Biologics · doi:10.3390/biologics5010007 · Cited by 9

Ketamine for depression: a potential role in requests for Medical Aid in Dying?

Garel, N., Nazon, M., Naghi, K., Willis, E., Looper, K. J., Rej, S., & Greenway, K. T. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000462 · Cited by 8

Exploring the potential of a bridge therapy: Synergistic approach integrating intravenous ketamine and intranasal esketamine for treatment‐resistant depression

d’Andrea, G., Pettorruso, M., Rhee, T. G., Lorenzo, G. D., McIntyre, R. S., & Martinotti, G. (2023) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13605 · Cited by 8

Guidelines for ketamine use in clinical psychiatry practice

Jelen, L. A., McShane, R. H., & Young, A. H. (2024) · BJPsych Open · doi:10.1192/bjo.2024.62 · Cited by 8

Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies

Pulido-Saavedra, A., Oliva, H. N. P., Prudente, T. P., Kitaneh, R., Nunes, E. J., Fogg, C., Funaro, M. C., Weleff, J., Nia, A. B., & Angarita, G. A. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05519-2 · Cited by 9

Esketamine reduces postoperative depression in breast cancer through TREK-1 channel inhibition and neurotransmitter modulation

Xu, J., Li, M., Hu, Y., Yang, Q., Long, Q., & Zhou, H. X. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03664-7 · Cited by 7

Connecting the dots: Understanding and addressing the metabolic impact of antipsychotic and antidepressant medications

Miedlich, S. U., & Lamberti, J. S. (2025) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15301 · Cited by 9

Effect of Esketamine-Based Opioid-Sparing Anesthesia Protocol on the Quality of Early Recovery After Urological Surgery: A Randomized Clinical Trial

Qi, Y., Li, W., Ren, Y., Sun, J., Zhu, Y., Wang, L., Zhou, M., & Wang, L. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s511112 · Cited by 7

A cell-type-specific circuit of somatostatin neurons in the habenula encodes antidepressant action in male mice

Luo, L., Jing, W., Guo, Y., Liu, D., He, A., & Lu, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-58591-y · Cited by 8

The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine

Park, D., Lee, G., Lee, W.-G., Kim, B. S., Lee, Y., & Kim, J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03100-2 · Cited by 11

Ketamine and Esketamine in Treatment-Resistant Depression: A New Era of Rapid-Acting Antidepressants

Shuxratovna, S. S. (2025) · International Journal of Pediatrics and Genetics

Ketamine and esketamine for treatment-resistant depression: A systematic review of published studies

Rogała, J., Polityńska, K., Ruszel, D., Sarzyńska, M., Samuła, K., Goc, E., Markuszka, K., Lepak, S., Irzyk, Z., & Szabat, M. (2026) · Medical Science · doi:10.54905/disssi.v30i174.e142ms3863

Ketamine and Esketamine in Treatment of Resistant Depression

Prosowski, J., Pośpiech, S., Piotrowski, M., Serwicki, P., & Początek, J. (2024) · Archiv Euromedica · doi:10.35630/2024/14/6.611

Ketamine Treatment for Depression: A Review

Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022) · Discover Mental Health · doi:10.1007/s44192-022-00012-3 · Cited by 161

Comparative study of esketamine and racemic ketamine in treatment-resistant depression

Correia‐Melo, F. S., Leal, G. C.-G., Carvalho, M. S., Jesus‐Nunes, A. P., Ferreira, C. B., Vieira, F., Magnavita, G. M., Vale, L. A. S., Mello, R. P., Nakahira, C., et al. (2018) · Medicine · doi:10.1097/md.0000000000012414 · Cited by 61